Pfizer Inc

NYSE: PFE
$25.65
+$0.52 (+2.1%)
Closing Price on November 22, 2024

PFE Articles

For the second consecutive trading day, all 30 Dow stocks closed lower Thursday. Exxon, Chevron, Pfizer, and McDonald's were the biggest losers.
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
Pfizer shares slipped on Monday despite the company posting positive results from a late-stage tafamidis trial.
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
The FDA is extending the expiration dates for certain EpiPens in light of the national shortage ahead of the back-to-school season.
Caterpillar, Apple, Pfizer, and Cisco were Friday's top-gaining Dow stocks.
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
Merrill Lynch now recommends these five outstanding dividend-paying U.S. stocks with solid upside potential.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.